OpenEvidence is the most popular AI for doctors in the United States. Founded with the mission to organize and expand the world's collective medical knowledge.
Over 85% of oncologists at Memorial Sloan Kettering Cancer Center use OpenEvidence.
Together, @MSKCancerCenter and OpenEvidence have built OncoKB, MSK’s expert interpretation of a tumor’s genetics, directly into OpenEvidence, putting it in the hands of oncologists across the United States.
As Dr. Anaeze Offodile puts it: “Our mission is to end cancer for life.” As of today, we are widening OncoKB’s reach so that patients everywhere benefit from the same rigor as patients at MSK. Watch the story.
We know Patients are using AI tools to get information about their health. At OpenEvidence, we have long talked about building a tool for patients with the same evidence engine clinician is using. Excited to study such a tool with Apple during this collab
From @WSJopinion: Doctors have a new assistant. OpenEvidence, an AI-powered platform, is helping physicians and saving lives, writes @andykessler.
on.wsj.com/3Vtaldy
BREAKING NEWS!
What a Monday morning! Apple and OpenEvidence just launched an experimental health chat app
The Apple Health AI Usage Study app was designed to answer health questions only using trusted medical research and based on your health metrics and records.
"The study will also explore how health AI can potentially help participants better prepare for clinical visits with their own doctors and will ask the user for feedback along the way about how the experience is going.
For example, someone asking how to improve their resting heart rate could receive advice based on their own health measurements, rather than general recommendations."
It's big news for both companies! Apple wants to use AI to help its users get the medical information and health insights they need, similarly to how ChatGPT launched ChatGPT Health and Anthropic launched Claude for healthcare.
OpenEvidence so far has been focusing on building AI for medical professionals and now turns towards general consumers too.
The question is whether this collaboration is going to mean enough trust for Apple users to share their health data and use the service.
If you are an Apple user, please share your thoughts!
Source: abcnews.com/US/apple-launche…
We are so thrilled about this partnership with @OpenEvidence, the physicians we'll be able to reach, and the impact we'll be able to make for patients!
Excited to work with Daniel Nadler and his team on this important mission!
When Every Cure’s programs reach trials, OpenEvidence will flag when a patient may qualify. The treating physician decides whether to refer. Read full announcement: businesswire.com/news/home/2…
The drug that saved @DavidFajgenbaum's life has been on pharmacy shelves for decades. It was approved for kidney transplants. He nearly died of Castleman disease and had been told there was nothing left to try.
Thousands of diseases have no FDA-approved treatment. For some of them, the answer may already be sitting in a pharmacy. Nobody has run the trial.
@EveryCure, the nonprofit he co-founded, exists to run these trial. Starting today, we’re working with them. OpenEvidence will help evaluate repurposing hypotheses, connect each program with the few physicians who actually treat the disease, and bring trial results back to the point of care when they land.
Many of these are generic drugs. No one has a commercial reason to study them. That is exactly why a nonprofit has to.
“OpenEvidence is the most trusted and loved brand product among doctors. Apple is the most trusted and loved brand and product among consumers, and especially health consumers. So you have to bring these two things together. It’s like peanut butter and jelly.”
--OpenEvidence CEO Daniel Nadler
In @WSJ, @andykessler explores how AI is supporting physicians and reshaping modern medicine. OpenEvidence mission remains simple: unburdening doctors with trusted, peer-reviewed evidence so they can stay focused on their patients.
wsj.com/opinion/doctors-have…
Guidelines tell us what to do with new data. They're much less help with the patient in clinic who never would have made it into the trial.
@OpenEvidence and the Uromigos are bringing expert opinion in to help with those gaps. It doesn't replace the guidelines 🤝. Look forward to see this roll out
#urovoices#uromigos
While the end user of OpenEvidence is a clinician, everything we do is in service of providing those providers and, subsequently, their patients, with the resources they need to make informed decisions. Today, we take a big step into incorporating more resources beyond clinical evidence to support those decisions with Access Intelligence.
A prescription the patient can't afford, or the payer won't approve, doesn't treat anything.
Today we launched Access Intelligence: copay savings, patient assistance, program enrollment, and prior authorization, inside OpenEvidence. Free for all clinicians.
The help exists. There are thousands of support programs, and prior auths can be won. But the work is scattered across payers and programs, each with its own forms and criteria, and you have a few minutes per patient.
What's live now:
* Ask about availability and eligibility across 2,500+ patient support programs, updated daily.
* Send copay savings and discount offers to the patient with Patient TakeHome.
* Download pre-populated enrollment forms, or enroll on OpenEvidence.
* Write prior auth requests, appeals, and letters of medical necessity grounded in clinical guidelines, with PA checklists and relevant ICD-10 codes.
Choosing the right treatment should be the hardest part of getting a patient treated.